Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Morgan Stanley 22nd Annual Global...
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
August 07, 2024 07:00 ET
|
Madrigal Pharmaceuticals, Inc.
Second-quarter 2024 net sales of $14.6 million Rezdiffra™ (resmetirom) coverage in place for more than 50 percent of commercial lives; less than 5 percent of Rezdiffra-covered lives require...
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
August 02, 2024 07:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
July 24, 2024 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August...